SBC Medical added to membership of Russell 3000® Index
IRVINE, Calif.--(BUSINESS WIRE)--Jun 27, 2025--
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/
Yoshiyuki Aikawa-Director (Chairman), CEO
Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.
For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website.
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.
For more information, visit https://sbc-holdings.com/
About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at www.sec.gov.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608244276/en/
CONTACT: SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail:[email protected] LLC (In the US)
Bill Zima / Managing Partner Email:[email protected]
KEYWORD: SOUTHEAST ASIA SINGAPORE NORTH AMERICA ASIA PACIFIC JAPAN EUROPE UNITED STATES UNITED KINGDOM CALIFORNIA
INDUSTRY KEYWORD: MEDICAL SUPPLIES TECHNOLOGY PROFESSIONAL SERVICES OTHER HEALTH HEALTH HEALTH TECHNOLOGY MEDICAL DEVICES COSMETICS RETAIL DATA ANALYTICS SOFTWARE
SOURCE: SBC Medical Group Holdings Incorporated
Copyright Business Wire 2025.
PUB: 06/27/2025 07:30 PM/DISC: 06/27/2025 07:31 PM
http://www.businesswire.com/news/home/20250608244276/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Plans unveiled for NHS funding to be linked to patient feedback
NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."
Yahoo
20 minutes ago
- Yahoo
Can CrowdStrike Stock Keep Moving Higher in 2025?
CrowdStrike's all-in-one Falcon cybersecurity platform is increasingly popular for businesses, and it has a substantial long-term growth runway. However, CrowdStrike stock is trading at a record high following a 40% gain this year, and its valuation is starting to look a little rich. Investors hoping for more upside in 2025 might be left disappointed, but there is still an opportunity here for those with a longer time horizon. 10 stocks we like better than CrowdStrike › CrowdStrike (NASDAQ: CRWD) is one of the world's biggest cybersecurity companies. Its stock has soared 40% year to date, but its current valuation might be a barrier to further upside for the remainder of the year. With that said, investors who are willing to take a longer-term view could still reap significant rewards by owning a slice of CrowdStrike. The company's holistic all-in-one platform is extremely popular with enterprise customers, and its annual recurring revenue (ARR) could more than double over the next six years based on a forecast from management. The cybersecurity industry is quite fragmented, meaning many providers often specialize in single products like cloud security or identity security, so businesses have to use multiple vendors to achieve adequate protection. CrowdStrike is an outlier in that regard because its Falcon platform is a true all-in-one solution that allows its customers to consolidate their entire cybersecurity stack with one vendor. Falcon uses a cloud-based architecture, which means organizations don't need to install software on every computer and device. It also relies heavily on artificial intelligence (AI) to automate threat detection and incident response, so it operates seamlessly in the background and requires minimal intervention, if any, from the average employee. To lighten the workload for cybersecurity managers specifically, CrowdStrike launched a virtual assistant in 2023 called Charlotte AI. It eliminates alert fatigue by autonomously filtering threats, which means human team members only have to focus on legitimate risks to their organization. Charlotte AI is 98% accurate when it comes to triaging threats, and the company says it's saving managers more than 40 hours per week on average right now. Falcon features 30 different modules (products), so businesses can put together a custom cybersecurity solution to suit their needs. At the end of the company's fiscal 2026 first quarter (ended April 30), a record 48% of its customers were using six or more modules, up from 44% in the year-ago period. It launched a new subscription option in 2023 called Flex, which allows businesses to shift their annual contracted spending among different Falcon modules as their needs change. This can save customers substantial amounts of money, and it also entices them to try modules they might not have otherwise used, which can lead to increased spending over the long term. This is driving what management calls "reflexes," which describes Flex customers who rapidly chew through their budgets and come back for more. The company says 39 Flex customers recently exhausted their budgets within the first five months of their 35-month contracts, and each of them came back to expand their spending. It ended the fiscal 2026 first quarter with a record $4.4 billion in ARR, which was up 22% year over year. That growth has slowed over the last few quarters, mainly because of the major Falcon outage on July 19 last year, which crashed 8.5 million customer computers. Management doesn't anticipate any long-term effects from the incident (which I'll discuss further in a moment) because Falcon is so valuable to customers, but the company did offer customer choice packages to affected businesses that included discounted Flex subscriptions. This is dealing a temporary blow to revenue growth. Here's where things get a little sticky for CrowdStrike. Its stock is up over 40% this year and is trading at a record high, but the strong move has pushed its price-to-sales ratio (P/S) up to 29.1 as of June 24. That makes it significantly more expensive than any of its peers in the AI cybersecurity space: This premium valuation might be a barrier to further upside for the rest of this year, and it seems Wall Street agrees. The Wall Street Journal tracks 53 analysts who cover the stock, and their average price target is $481.95, which is slightly under where it's trading now, implying there could be near-term downside. But there could still be an opportunity here for longer-term investors. As I mentioned earlier, management doesn't expect any lingering impacts from the Falcon outage last year because it continues to reiterate its goal to reach $10 billion in ARR by fiscal 2031. That represents potential growth of 127% from the current ARR of $4.4 billion, and if the forecast comes to fruition, it could fuel strong returns for the stock over the next six years. Plus, $10 billion is still a fraction of CrowdStrike's estimated addressable market of $116 billion today -- a figure management expects to more than double to $250 billion over the next few years. So while I don't think there's much upside on the table for CrowdStrike in the remainder of 2025, those who can hold on to it for the next six years and beyond still have a solid investment opportunity. Before you buy stock in CrowdStrike, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CrowdStrike wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CrowdStrike and Zscaler. The Motley Fool recommends Palo Alto Networks. The Motley Fool has a disclosure policy. Can CrowdStrike Stock Keep Moving Higher in 2025? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Cantor Fitzgerald Reiterates a Hold Rating on Alphabet (GOOG)
Alphabet Inc. (NASDAQ:GOOG) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. In a report released on June 25, Deepak Mathivanan from Cantor Fitzgerald reiterated a Hold rating on Alphabet Inc. (NASDAQ:GOOG) with a price target of $171.00. The company's fiscal Q1 2025 results showed a 12% year-over-year growth in consolidated revenues to $90.2 billion, with double-digit growth rates reported in Google Search & other, YouTube ads, Google subscriptions, platforms, and devices, as well as Google Cloud. Net income for the quarter rose 46%, and EPS grew 49% to $2.81. A laptop and phone open to Google's services in an everyday setting. Alphabet Inc. (NASDAQ:GOOG) also reported a 28% rise in Google Cloud revenues to $12.3 billion, attributed to growth in Google Cloud Platform (GCP) across core GCP products, AI Infrastructure, and Generative AI Solutions. Alphabet Inc. (NASDAQ:GOOG) is a holding company with segments including Google Services, Google Cloud, and Other Bets. The Google Services segment operates various services and products, including Android, Google Maps, Google Play, Chrome, Search, and YouTube. While we acknowledge the potential of GOOG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
